"So from a public health perspective, it is an ideal situation. We are looking to see if we can create a vaccine that covers Omicron and doesn't forget the other variants and that could be a solution," Bourla said.
Pfizer/BioNtech's COVID-19 vaccine has shown to be effective against severe disease and death caused by the heavily-mutated Omicron variant but less effective in preventing transmission.
Bourla has said Pfizer could be ready to file for approval for a redesigned vaccine to fight Omicron, and mass produce it, as soon as March.
With cases soaring, some countries have expanded COVID-19 vaccine booster programs or shortened the gap between shots as governments scramble to shore up protection.
In an interview with Israel's N12 News, Bourla was asked whether he sees booster shots being administered every four to five months on a regular basis.
"This will not be a good scenario. What I'm hoping (is) that we will have a vaccine that you will have to do once a year," Bourla said.
"Once a year — it is easier to convince people to do it. It is easier for people to remember.